Name: ADCT Income Statement - Adc Therapeutics SA Revenue & EPS | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Revenue, Cost of Revenue, Gross Profit, Operating Expenses, Operating Income, Net Income, EPS Basic, EPS Diluted

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

ADCT - Adc Therapeutics SA

USD | NYSE | Healthcare

ADCT Income Statement - Adc Therapeutics SA Revenue & EPS | Ledgeburg

(in millions of USD, except per-share data)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q2 FY 23	Q1 FY 23	Q3 FY 22	Q2 FY 22
Revenues
Revenues	20.9	23.1	16.4	18.8	23.0	16.9	18.5	17.4	18.1	16.8	14.5	19.3	19.0	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses
Research & Development	19.9	18.2	26.8	30.1	28.9	27.1	32.5	24.3	25.7	30.3	27.1	31.3	38.4	-	-
Operating Income
Operating Income	(25.2)	(17.9)	(31.0)	(44.1)	(28.5)	(32.4)	(35.6)	(29.0)	(33.6)	(40.0)	(36.1)	(39.6)	(50.2)	-
Non-Operating
Interest Income	2.0	2.4	2.5	1.9	2.1	2.6	3.4	3.3	2.9	3.3	2.7	2.4	2.2	-	-
Tax & Net
Income Tax Expense	0.0	(0.4)	0.0	1.3	0.2	(0.3)	0.1	0.2	0.2	43.2	(0.1)	(4.5)	0.5	-	-
Per Share
EPS Basic	(0.21)	-	(0.30)	(0.50)	(0.36)	-	(0.42)	(0.38)	(0.56)	-	(0.57)	(0.60)	(0.73)	-	-
EPS Diluted
Supplementary Data
EBITDA	-	(17.9)	(31.0)	(43.8)	(28.1)	(32.1)	(35.2)	(28.7)	(33.3)	(39.6)	(35.8)	(39.4)	(49.9)	-	-
EBIT

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD, except per-share data)	TTM	FY2025	FY2024	FY2023	FY2022
Revenues
Revenues	79.2	81.4	70.8	69.6	209.9
Cost of Revenue	-	5.8

Operating Expenses
Research & Development	95.0	104.0	109.6	127.1	186.5
Selling General & Administrative	-	-	-	-	-
Selling & Marketing	45.5	43.4	44.0	57.5	69.1
General & Administrative	36.5	36.6	41.9	48.4	74.4
Depreciation & Amortization	-	0.7	1.3	1.2	1.1
Amortization of Intangibles	-	-	-	-	-
Other Operating Expenses	-	-	-	-	-
Total Operating Expenses	197.5	202.9	201.5	235.5	333.3

Operating Income
Operating Income	(118.3)	(121.5)	(130.7)	(166.0)	(123.3)

Non-Operating
Interest Income	8.8	8.8	12.3	10.5	2.6
Interest Expense	51.8	51.6	50.2	46.3	36.7
Income From Equity Investments	-	0.0	(1.5)	(5.5)	(10.1)
Other Non-Operating Income	(17.9)	(20.1)	(25.5)	(29.4)	(23.5)
Pre-Tax Income	(136.1)	(141.6)	(156.1)	(195.4)	(146.8)

Tax & Net
Income Tax Expense	0.9	1.0	0.2	39.1	0.2
Net Income From Continuing Ops	(137.0)	(142.6)	(157.8)	(240.1)	(157.1)
Net Income From Discontinued Ops	-	-	-	-	-
Net Income	(137.0)	(142.6)	(157.8)	(240.1)	(157.1)
Net Income Attributable To Parent	(137.0)	(142.6)	(157.8)	(240.1)	(157.1)
Less: Minority Interest	-	-	-	-	-
Less: Preferred Dividends	-	-	-	-	-
Net Income To Common Shareholders	(137.0)	(142.6)	(157.8)	(240.1)	(157.1)

Per Share
EPS Basic	(0.89)	(1.12)	(1.62)	(2.94)	(2.01)
EPS Diluted	(0.89)	(1.12)	(1.62)	(2.94)	(2.01)
Shares Basic	154.1	127.1	97.2	81.7	78.2
Shares Diluted	154.1	127.1	97.2	81.7	78.2

Supplementary Data
EBITDA	-	(120.8)	(129.3)	(164.8)	(122.3)
EBIT	(118.3)	(121.5)	(130.7)	(166.0)	(123.3)